Drugs / Temozolamide
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01743157 | Dec 2010 → May 2013 | metastatic melanoma | California Pacific Medical Center Research Institute | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT01308632 | Nov 2007 → Jun 2012 | glioblastoma | Grupo Español de Investigación en Neurooncología | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07185672 | Aug 2019 → Aug 2027 expected | digestive system neuroendocrine neoplasm | Tata Memorial Hospital | Recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | temozolamide | “Temozolamide 150mg/m2 x4, cisplatin 20mg/m2 x 4, vinblastine 1.2mg/m2 x 4, bevacizumab 7.5-15 mg/kg x 1, interferon 5mg/m2 x5 and aldesleukin 36,18,9, % 9 miu/day over 4 days...” NCT01743157 ↗ |